Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONCERT PHARMACEUTICALS, INC.CNCE · Entity 115906 | Chief Financial Officer | January 04, 2017 | January 06, 2017 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Chief Financial Officer | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONCERT PHARMACEUTICALS, INC.
Report date January 04, 2017 · Filed January 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.97 · Expires 2027-01-03 | Direct | 82,500 |
Reported balance
After 2017-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-04 · Grant · Acquired 82,500 · Balance 82,500 F1: This option vests in sixteen equal quarterly installments beginning on April 4, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in sixteen equal quarterly installments beginning on April 4, 2017.
enGene Therapeutics Inc.
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.53 · Expires 2036-01-30 | Direct | 220,000 |
Reported balance
After 2026-01-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 220,000 · Balance 220,000 F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 30, 2026 Filed Feb 3, 2026 16:10 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 220,000 | $0.00 Strike: $9.53 | $0.00 |
DisclosureSEC source: 0000929638-26-000481 · form4.xml · derivative · entry 1 Daws D. Ryan · CIK 0001598602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Shares · 220,000 shares Expires 2036-01-30 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| January 29, 2025 Filed Jan 31, 2025 16:40 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0000929638-25-000478 · form4.xml · derivative · entry 1 Daws D. Ryan · CIK 0001598602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Shares · 280,000 shares Expires 2035-01-29 F1 · derivative.exercise_date: This option vests monthly in substantially equal amounts for 48 months, subject to the reporting person's continued service. Read SEC document |
| November 30, 2023 Filed Dec 4, 2023 17:52 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 232,000 | $0.00 Strike: $7.66 | $0.00 |
DisclosureSEC source: 0000929638-23-003339 · form4.xml · derivative · entry 1 Daws D. Ryan · CIK 0001598602 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,000 Underlying: Common Shares · 232,000 shares Expires 2033-11-30 F1 · derivative.exercise_date: This option vests at 25% on the first anniversary of the grant date, with the remaining portion to vest monthly over the remaining three years. Read SEC document |
| January 04, 2017 Filed Jan 6, 2017 17:03 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantEmployee Stock Option (right to buy) · Derivative | 82,500 | $0.00 Strike: $10.97 | $0.00 |
DisclosureSEC source: 0001209191-17-002680 · doc4.xml · derivative · entry 1 Daws D. Ryan · CIK 0001598602 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,500 Underlying: Common Stock · 82,500 shares Expires 2027-01-03 F1 · derivative.exercise_date: This option vests in sixteen equal quarterly installments beginning on April 4, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.